Hepatitis C - AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HC

AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HC
Doctors Guide - Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S. dose-ranging Phase Ib study of VX-950 dosed in an oral suspension for 14 days in patients with chronic hepatitis C. Dr.

ViroPharma Announces That Treatment With HCV-796 Reduces Hepatitis C Virus Levels
Primezone Media Network - NYSE:WYE). In this trial, HCV-796 demonstrated antiviral effects in adult patients with chronic hepatitis C infection

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Com
Canada NewsWire - Results Reported at American Association for the Study of Liver Diseases (AASLD) Meeting Large Phase II Combination Study Under Way SAN FRANCISCO, Nov. representing an area of great unmetmedical need. Chronic hepatitis C affects more than 10 million people inmajor world